Who We Are
Frezent is a preclinical-stage oncology therapeutics company developing first-in-class biologics, inhibiting cancer metabolism to combat residual disease and decrease the risk of cancer recurrence.
-
At Frezent, our mission is to develop first-in-class biologics that selectively eliminate residual cancer cells—both proliferating and dormant— to deliver complete therapeutic response, prevent relapse, and extend progression-free survival. By selectively targeting cancer-specific metabolic pathways with precision, we are committed to transforming post-treatment oncology care and giving cancer survivors greater confidence in sustained remission.
-
Our vision is a future where cancer recurrence is no longer an expected risk, but a preventable outcome. Frezent strives to redefine survivorship by developing therapies that proactively treat residual disease early and improve long-term patient outcomes — bringing lasting peace of mind to millions of survivors and their families worldwide.